3 Drugs Stocks Pushing Industry Growth

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 57 points (-0.3%) at 17,793 as of Monday, June 8, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,037 issues advancing vs. 1,919 declining with 182 unchanged.

The Drugs industry currently sits up 0.8% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include China Biologic Products ( CBPO), down 8.2%, Incyte ( INCY), down 2.2%, Novo Nordisk A/S ( NVO), down 1.6% and AstraZeneca ( AZN), down 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Eli Lilly and ( LLY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Eli Lilly and is up $0.63 (0.8%) to $78.75 on average volume. Thus far, 1.8 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $77.83-$78.85 after having opened the day at $77.98 as compared to the previous trading day's close of $78.12.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. Eli Lilly and has a market cap of $86.2 billion and is part of the health care sector. Shares are up 13.2% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Celgene ( CELG) is up $1.92 (1.7%) to $112.64 on average volume. Thus far, 2.5 million shares of Celgene exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $110.80-$113.09 after having opened the day at $111.01 as compared to the previous trading day's close of $110.72.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $88.0 billion and is part of the health care sector. Shares are down 1.0% year-to-date as of the close of trading on Friday. Currently there are 13 analysts who rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and notable return on equity. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Celgene Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, AbbVie ( ABBV) is up $0.41 (0.6%) to $67.81 on light volume. Thus far, 3.9 million shares of AbbVie exchanged hands as compared to its average daily volume of 11.9 million shares. The stock has ranged in price between $67.53-$67.93 after having opened the day at $67.87 as compared to the previous trading day's close of $67.40.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $107.4 billion and is part of the health care sector. Shares are up 3.0% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full AbbVie Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%